Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
Paula Soria‐Chacartegui, Gonzalo Villapalos‐García, Pablo Zubiaur, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics
X.M. Hart, Gerhard Gründer, Nicolas Ansermot, et al.
The World Journal of Biological Psychiatry (2024) Vol. 25, Iss. 9, pp. 451-536
Closed Access | Times Cited: 9
Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications
Mohitosh Biswas, Natchaya Vanwong, Chonlaphat Sukasem
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 4
The Implications of Cytochrome P450 2D6/CYP2D6 Polymorphism in the Therapeutic Response of Atypical Antipsychotics in Adolescents with Psychosis—A Prospective Study
Adriana Cojocaru, Adina Braha, Roxana Maria Jeleriu, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 494-494
Open Access | Times Cited: 4
Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients
Cun Zhang, Lei Jiang, Ke Hu, et al.
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 479-490
Open Access | Times Cited: 4
Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics
Liam Korošec Hudnik, Tanja Blagus, Sara Redenšek, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 4
Redefining the Cut-Off Ranges for TSH Based on the Clinical Picture, Results of Neuroimaging and Laboratory Tests in Unsupervised Cluster Analysis as Individualized Diagnosis of Early Schizophrenia
Natalia Śmierciak, Marta Szwajca, T Popiela, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 2, pp. 247-247
Open Access | Times Cited: 18
Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms
Adriana Stelmach, Katarzyna Guzek, Alicja Rożnowska, et al.
Pharmacological Reports (2022) Vol. 75, Iss. 1, pp. 19-31
Open Access | Times Cited: 17
CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients
Ferenc Fekete, Ádám Menus, Katalin Tóth, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Direct Effects of Antipsychotics on Potassium Channels
Wenwen Zhuang, Seo‐Yeong Mun, Won Sun Park
Biochemical and Biophysical Research Communications (2025) Vol. 749, pp. 151344-151344
Closed Access
Drug-drug interaction of paroxetine on olanzapine and initial dosage optimization in patients with major depressive disorder based on population pharmacokinetics
Cun Zhang, Liang Chen, Yuanyuan Duan, et al.
Frontiers in Psychiatry (2025) Vol. 16
Open Access
Artificial Intelligence for Drug Toxicity and Safety
Shivanjali Joshi-Barr, Matthew E. Wampole
Springer eBooks (2024), pp. 2637-2671
Closed Access | Times Cited: 3
Optimizing Chronotherapy in Psychiatric Care: The Impact of Circadian Rhythms on Medication Timing and Efficacy
Cezar-Ivan Coliță, Dirk M. Hermann, Mădălina Fîlfan, et al.
Clocks & Sleep (2024) Vol. 6, Iss. 4, pp. 635-655
Open Access | Times Cited: 3
Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions
Priyanka Kolli, Grace Kelley, Marianela Rosales, et al.
Pharmacogenomics and Personalized Medicine (2023) Vol. Volume 16, pp. 1097-1108
Open Access | Times Cited: 7
Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
Olga Płaza, Piotr Gałecki, Agata Orzechowska, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3165-3165
Open Access | Times Cited: 11
Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain
Bruna Panizzutti, Chiara C. Bortolasci, Briana Spolding, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 18, pp. 4095-4095
Open Access | Times Cited: 13
A Computational Understanding of Inter-Individual Variability in CYP2D6 Activity to Investigate the Impact of Missense Mutations on Ochratoxin A Metabolism
J.L.C.M. Dorne, Martina Cirlini, Jochem Louisse, et al.
Toxins (2022) Vol. 14, Iss. 3, pp. 207-207
Open Access | Times Cited: 10
Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review
Glauco Valdivieso-Jiménez, Dennis Anthony Pino-Zavaleta, Susan K. Campos-Rodriguez, et al.
Psychiatric Quarterly (2023) Vol. 94, Iss. 4, pp. 541-557
Open Access | Times Cited: 4
Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder
Mohitosh Biswas, Natchaya Vanwong, Chonlaphat Sukasem
Pharmacogenomics (2022) Vol. 23, Iss. 8, pp. 493-503
Open Access | Times Cited: 7
Dopamine in the pathophysiology and treatment of schizophrenia
Kainan Wang
(2024), pp. 26-26
Closed Access | Times Cited: 1
Increased antipsychotic drug concentration in hospitalized patients with mental disorders following COVID-19 infection: a call for attention
Rui Yang, Jin-Ling Wan, Chen-Qi Pi, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 1
Coadministration of Cariprazine with a Moderate CYP3A4 Inhibitor in Patients with Schizophrenia: Implications for Dose Adjustment and Safety Monitoring
M Szabó, Zoltán Hujber, Judit Harsányi, et al.
Clinical Pharmacokinetics (2024)
Open Access | Times Cited: 1
EFEITOS COLATERAIS DOS ANTIPSICÓTICOS DE SEGUNDA GERAÇÃO: UMA ANÁLISE COMPARATIVA ENTRE BULAS E EVIDÊNCIAS CLÍNICAS
Márcia Regina Batista, CARLA REGINA DA SILVA CORRÊA DA RONDA, SILVIA BANDIERA BORGES, et al.
(2024)
Open Access | Times Cited: 1
Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug
Xiaoling Zhang, Jieer Ying
Current Oncology (2022) Vol. 29, Iss. 11, pp. 8235-8243
Open Access | Times Cited: 6
Safety outcomes of antipsychotics classes in drug-naïve patients with first-episode schizophrenia: A nationwide cohort study in South Korea
Dong Yun Lee, Chungsoo Kim, Dong Han Yu, et al.
Asian Journal of Psychiatry (2023) Vol. 91, pp. 103857-103857
Closed Access | Times Cited: 3
Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients
Xueping Wang, Dongli Mei, Zhe Lu, et al.
Schizophrenia (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top